IP Library › Granted Patent US 11,833,213
Granted Patent B2
US 11,833,213 · App. 17/236,722 · Granted Dec 5, 2023

Compositions and methods for the treatment of viral infections

Inventors: James M. Balkovec (Martinsville, NJ); Daniel C. Bensen (Carlsbad, CA); Allen Borchardt (San Diego, CA); Thomas P. Brady (San Diego, CA); Zhi-Yong Chen (La Jolla, CA); Jason Cole (San Diego, CA); Quyen-Quyen Thuy Do (San Diego, CA); Simon Doehrmann (San Diego, CA); Wanlong Jiang (San Diego, CA); Thanh Lam (San Diego, CA); Alain Noncovich (La Jolla, CA); Leslie W. Tari (Solana Beach, CA)
Assignee: Cidara Therapeutics, Inc.
A61K47/68
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,833,213
App. No.
17/236,722
Granted
Dec 5, 2023
Kind
B2
Abstract

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

Claims (16)

1. A conjugate described by formula (D-I):

wherein each of A1 and A2 is zanamivir;

E comprises an Fc domain monomer comprising an amino acid sequence selected from any one of SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 67, and SEQ ID NO: 68, wherein each Fc domain optionally lacks C-terminal Lys447;

L is a linker covalently attached to each of A1, A2, and E, wherein L is covalently attached to each of A1 and A2 independently at position C7 or position C9 of zanamivir;

n is 1 or 2; and

T is the number of A 1 -L-A 2 moieties conjugated to each E and each T is, independently, an integer from 1 to 20;

or a pharmaceutically acceptable salt thereof.

2. The conjugate of claim 1 , wherein each L is covalently attached to the nitrogen atom of a surface exposed lysine of E.

3. The conjugate of claim 1 , wherein each L is covalently attached to the sulfur atom of a surface exposed cysteine of E.

4. The conjugate of claim 1 , wherein n is 2, and the two Es dimerize with each other to form an Fc domain.

5. The conjugate of claim 1 , wherein T is an integer from 1 to 10.

6. A population of conjugates of claim 1 , wherein the average value of T is 1 to 5.

7. The conjugate of claim 1 , wherein each E comprises an amino acid sequence of SEQ ID NO: 63.

8. The conjugate of claim 1 , wherein each E comprises an amino acid sequence of SEQ ID NO: 64.

9. The conjugate of claim 1 , wherein each E comprises an amino acid sequence of SEQ ID NO: 67.

10. The conjugate of claim 1 , wherein each E comprises an amino acid sequence of SEQ ID NO: 68.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2021
From: BALKOVEC, JAMES M.; BENSEN, DANIEL C.; BORCHARDT, ALLEN; BRADY, THOMAS P.; CHEN, ZHI-YONG; COLE, JASON; DO, QUYEN-QUYEN THUY; DOEHRMANN, SIMON; JIANG, WANLONG; LAM, THANH; NONCOVICH, ALAIN; TARI, LESLIE W.
To: CIDARA THERAPEUTICS, INC.
Reel/Frame 057257/0797 →
Continuity (15)
Continuation 17193923 · Mar 5, 2021
Continuation PCTUS2019050018 · Sep 6, 2019
Provisional Application 62890475 · Aug 22, 2019
Provisional Application 62873678 · Jul 12, 2019
Provisional Application 62859983 · Jun 11, 2019
Provisional Application 62852075 · May 23, 2019
Provisional Application 62840899 · Apr 30, 2019
Provisional Application 62832992 · Apr 12, 2019
Provisional Application 62815235 · Mar 7, 2019
Provisional Application 62813463 · Mar 4, 2019
Provisional Application 62788386 · Jan 4, 2019
Provisional Application 62782119 · Dec 19, 2018
Provisional Application 62746865 · Oct 17, 2018
Provisional Application 62727821 · Sep 6, 2018
Related Publication 20220257787A1 · Aug 18, 2022
Cited By (2)
US 12,427,200 US 12,569,565